OPKO Health - OPK Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued twelve-month target prices for OPKO Health's stock. Their OPK share price forecasts range from $3.00 to $4.00. On average, they expect the company's share price to reach $3.50 in the next year. This suggests a possible upside of 182.3% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.

OPKO Health's stock was trading at $1.25 on January 1st, 2023. Since then, OPK shares have decreased by 0.8% and is now trading at $1.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our OPK earnings forecast.

OPKO Health, Inc. (NASDAQ:OPK) posted its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company had revenue of $179.70 million for the quarter, compared to analyst estimates of $172.68 million. OPKO Health had a negative net margin of 25.98% and a negative trailing twelve-month return on equity of 14.79%.

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

OPKO Health's stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.07%), Sequoia Financial Advisors LLC (0.01%), Norris Perne & French LLP MI (0.01%), Transcend Capital Advisors LLC (0.01%), Shufro Rose & Co. LLC (0.00%) and RK Asset Management LLC (0.00%). Insiders that own company stock include Anthony J Japour, Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends.

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPK stock can currently be purchased for approximately $1.24.

OPKO Health (NASDAQ:OPK) has a market capitalization of $958.13 million and generates $1.22 billion in revenue each year. The biotechnology company earns $-30,140,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

The company employs 5,767 workers across the globe.

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.